• The Ticker
  • Message Boards
  • Jobs
  • Medtech[y] Shop
  • 
  • 
  • 
  • View
  • ALL
  • Biotech
  • Medical Device
  • Robotic Surgery
  • Medical Device Sales
  • Medtechy Deals
  • Future of Healthcare
  • Healthcare Fraud
  • Hospitals

Join Our Mailing List Today

Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine

Posted in Biotech by Medtech[y] Staff

February 28, 2020 • 2 min read

GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine...

Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Posted in Biotech by Medtech[y] Staff

February 27, 2020 • 2 min read

SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the fourth quarter and year ended Dec...

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Posted in Biotech by Medtech[y] Staff

February 27, 2020 • 2 min read

CAMBRIDGE, Mass. and BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration ag...

PROCEPT BioRobotics Announces Three-Year Follow-Up Data Confirming Sustained Efficacy, Superior Safety of Aquablation® Therapy for Benign Prostatic Hyperplasia

Posted in Medical Device by Medtech[y] Staff

February 27, 2020 • 2 min read

REDWOOD CITY, Calif.--(BUSINESS WIRE)--#bph--PROCEPT BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, has announced that three-year follow-up data from the blinded, randomized WA...

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

Posted in Biotech by Medtech[y] Staff

February 27, 2020 • 2 min read

PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated results from the combination ar...

Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome

Posted in Biotech by Medtech[y] Staff

February 27, 2020 • 2 min read

EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) ...

Amarin Stock Slides After Posting Better Than Expected Earnings and Revenue

Posted in Biotech by Medtech[y] Staff

February 26, 2020 • 2 min read

Amarin (NASDAQ:AMRN) was down as much as 10% after announcing fourth quarter and full year 2019 revenue after the close yesterday, showing significant growth and record revenue across both metrics....

Senseonics Announces the FDA Approval to Continue the PROMISE Sensor Clinical Study in an Extended Cohort to 365 Days to Gather Feasibility Data

Posted in Medical Device by Medtech[y] Staff

February 26, 2020 • 2 min read

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system ...

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

Posted in Biotech by Medtech[y] Staff

February 26, 2020 • 2 min read

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application...

Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Posted in Biotech by Medtech[y] Staff

February 25, 2020 • 2 min read

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and cl...

SUBMIT A TIP

Are you aware of fraud occurring at your workplace or previous place of employment?

Speak up, speak out, do the right thing.

REPORT HEALTHCARE FRAUD

TOP BOARD THREADS
  • Amarin EVAPORATE Study Results
    Amarin Message Board board
  • How do I get into Medical Device Sales?
    Medical Sales General Discussion board
  • What are the Best Biotech Stocks?
    Pharma/Biotech General Discussion board
  • FiercePharma's Top Pharma Companies in the World
    Pharma/Biotech Message Board board
  • Baker Brothers Advisors
    Pharma/Biotech General Discussion board
  • Will the FDA Approval Expanded Label for Vascepa?
    Amarin Message Board board
  • Is Amgen Looking to Acquire MannKind
    MannKind Message Board board
  • MedReps.com Jobs
    Medical Sales General Discussion board
  • Zimmer Biomet Layoffs
    Zimmer Biomet Message Board board
  • Medical Device Reps Back in the OR after COVID-19
    Medical Device Sales General Discussion board
  • READ MORE ON THE BOARDS

FEATURED JOBS
  • Medical Affairs Program Specialist
  • VIEW MORE JOBS

  • First Page
  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page
  • Last Page

Developed by medical sales professionals for medical sales professionals.

 •  @medtechy •  medtechy

copyright Medtechy Inc. ⋅ Report A Tip ⋅ Terms of Use ⋅ Privacy Policy ⋅ DMCA Policy ⋅ Removal Policy ⋅ [email protected]